Phase 2 Spinal Muscular Atrophy Trial, Recruiting NCT06290713 Sponsor: University of Florida Condition: Spinal Muscular Atrophy
Back to Spinal Muscular Atrophy

Phase 2 Spinal Muscular Atrophy Trial, Recruiting

NCT06290713
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Duchenne Muscular Dystrophy (DMD), confirmed by a genetic test report
  • You are at least 6 years old
  • You are able to walk
  • You have been on a stable steroid (glucocorticoid) treatment for more than 3 months

Who may not be able to join:

  • You are unable to have an MRI scan — for example, due to severe claustrophobia, having metal implants in your body, or being unwilling to do the test
  • You have serious or unstable health problems, such as severe heart muscle disease, poor heart pumping function, abnormal heart rhythm shown on a heart tracing (ECG), uncontrolled seizures, or uncontrolled very high or very low blood pressure
  • You have another condition that affects how your muscles work or use energy — for example, myasthenia gravis, a hormone disorder, or a mitochondrial disease
  • You have another condition that affects your development or movement control (such as cerebral palsy), or you have previously had a severe episode of muscle breakdown without a clear cause
  • You take certain medications that would not be safe to combine with the study drug — including nitrates, certain blood pressure medications called alpha-blockers, other similar drugs in the same class as the study drug, or any other medicines known to affect blood flow or muscle energy use (confirm with trial site)
  • You are currently taking part in another clinical trial or a trial for an FDA-approved treatment during the study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tanja Taivassalo, Ph.D., University of Florida, College of Medicine, Department of Physiology and Aging

Phone: 352-294-8748

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 June 2024
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Vascular responsiveness after muscle contraction to a single dose of tadalafil.; Cycling time to fatigue

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov